usually behave as benign proliferative lesion with no
malignant potential but in a few circumstances it can
undergo malignant transformation. Papapanagiotou
has reported malignant transformation of giant
condyloma at perianal area (Papapanagiotou, I.K.,
Migklis, K., Ioannidou, G., Xesfyngi, D., Kalles, V.,
Mariolis-Sapsakos, T., Terzakis, E., 2017). The
coexistence of condyloma with verrucous carcinoma
make it more complicated in diagnosis since the
benign process can contain focus of some malignant
cells making malignant marker was strongly required
for benign looking cases (ErmanVlahovic, M., Vlahovic,
J., Mrcela, M., Hrgovic, Z., 2017).
Sometimes microscopic examination with
hematoxylin-eosin staining cannot detect malignant
transformation. Huang has reported a giant
condyloma acuminatum with benign microscopic
feature give recurrent lesion with malignant feature
(Huang SM, Leung WH and Chen BF, 2007).
Therefore it need an additional staining to detect
microscopic malignancy that involve a few epithelial
cells.
Ki-67 protein which expressed in proliferating
cells has been used to determine tumor grade in many
cancer has potential ability to differentiate
malignancy from benign process and also useful for
detection focus of malignant transformation that arise
in benign lesion (Jonat W. and Arnold N, 2011).
5 CONCLUSION
Ki-67 staining is useful tool for differentiate
verrucous carcinoma from condyloma acuminatum
with 100 percent accuracy.
REFERENCES
Bambao, C., Nofech-Mozes, S., Shier, M., 2010. Giant
condyloma versus verrucous carcinoma: A case report.
Journal of Lower Genital Tract Disease 14, 230–233.
doi:10.1097/LGT.0b013e3181c945ed
ErmanVlahovic, M., Vlahovic, J., Mrcela, M., Hrgovic, Z.,
2017. Coexistence of Condylomata Acuminata with
Warty Squamous Cell Carcinoma and Squamous Cell
Carcinoma. Medical Archives 71, 72.
doi:10.5455/medarh.2017.71.72-75
Huang SM, Leung WH and Chen BF, 2007. Malignant
Transformation of Perianal Giant Condyloma
Acuminatum. J Soc Colon Rectal Surgeon (Taiwan)
18:23-30
Jonat W. and Arnold N, 2011. Is the Ki-67 labelling index
ready for clinical use? Annals of Oncology 22(3):500–
502.
Leblebici, C., Pasaoglu, E., Kelten, C., Darakci, S., Dursun,
N., 2017. Cytokeratin 17 and Ki-67:
Immunohistochemical markers for the differential
diagnosis of keratoacanthoma and squamous cell
carcinoma. Oncology Letters 13, 2539–2548.
doi:10.3892/ol.2017.5793
Li, L. T., Jiang, G., Chen, Q., Zheng, J. N, 2015. "Ki67 is a
promising molecular target in the diagnosis of cancer
(Review)". Molecular Medicine Reports 11:1566-1572.
Liu, G., Li, Q., Shang, X., Qi, Z., Han, C., Wang, Y., Xue,
F., 2016. Verrucous Carcinoma of the Vulva: A 20 Year
Retrospective Study and Literature Review. Journal of
Lower Genital Tract Disease 20, 114–118.
doi:10.1097/LGT.0000000000000164
Papapanagiotou, I.K., Migklis, K., Ioannidou, G., Xesfyngi,
D., Kalles, V., Mariolis-Sapsakos, T., Terzakis, E.,
2017. Giant condyloma acuminatum-malignant
transformation. Clinical Case Reports 5, 537–538.
doi:10.1002/ccr3.863
Scholzen, T., Gerdes, J., 2000. The Ki-67 protein: from the
known and the unknown. Scholzen T1, Gerdes J. J Cell
Physiol Mar, 311–322. doi:10.1002/(SICI)1097-
4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
Ki-67 Staining as a Tool to Differentiate Verrucous Carcinoma from Condyloma Acuminatum on Skin Biopsy
301